ITCI

Intra-Cellular Therapies (ITCI)

About Intra-Cellular Therapies (ITCI)

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Details

Daily high
$72.97
Daily low
$72.32
Price at open
$72.71
52 Week High
$84.89
52 Week Low
$45.50
Market cap
7.7B
Dividend yield
0.00%
Volume
264,594
Avg. volume
465,673
P/E ratio
-84.47

Intra-Cellular Therapies News

Details

Daily high
$72.97
Daily low
$72.32
Price at open
$72.71
52 Week High
$84.89
52 Week Low
$45.50
Market cap
7.7B
Dividend yield
0.00%
Volume
264,594
Avg. volume
465,673
P/E ratio
-84.47